AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

AbbVie and Allergan ... that the merged company would have too much market share in diseases such as Crohn's and ulcerative colitis, the European Commission asked Allergan to sell off brazikumab ...

Allergan has an attractive portfolio of beauty drugs, including Botox, which now belong to AbbVie. The combined company will have product lines spanning immunology, hematologic oncology ...

Allergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead of its $63 billion acquisition by AbbVie. The company announced ...